MedTrace Logo

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT01467375 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2017-02-24

No results posted yet for this study

Summary

This trial is conducted in Oceania and North America. The aim of this trial is to assess the long term safety and efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes who have completed the BIAsp-1234 trial.

Conditions

Interventions

DRUG

biphasic insulin aspart

Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-08
Primary Completion
2004-10-22
Completion
2004-10-22

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467375 on ClinicalTrials.gov